Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

GATA1 and GATA2 Sense/Antisense Transcriptional Switching in Early Hematopoietic Development

Erik M Anderson, Hongchuan Li, Michael Ruesch, Caprice D Eisele, Aharon G. Freud, Stephen K Anderson

Blood (2023) 142 (Supplement 1): 5578.

https://doi.org/10.1182/blood-2023-179519

Published: 2023

Journal Articles

In vivo HSC prime editing rescues sickle cell disease in a mouse model

Chang Li, Aphrodite Georgakopoulou, Gregory A. Newby, Peter J. Chen, Kelcee A. Everette, Kiriaki Paschoudi, Efthymia Vlachaki, Sucheol Gil, Anna K. Anderson, Theodore Koob, Lishan Huang, Hongjie Wang, Hans-Peter Kiem, David R. Liu, Evangelia Yannaki, André Lieber

Blood (2023) 141 (17): 2085–2099.

https://doi.org/10.1182/blood.2022018252

Published: 2023

Includes: Supplemental data

Journal Articles

Prediction of Clinical Response to Venetoclax Plus Decitabine in AML Using a 7-Day Ex Vivo Assay

Markus D Lacher, Michelle A Richardson, Steven A Schaffert, Ryosuke Kita, Marianne T Santaguida, Erica K Anderson, Jordan Roselli, Wade Anderson, Arisa Paul, Christine Gu, Kathryn Vanderlaag, Zhihong Zeng, Abhishek Maiti, Courtney D. DiNardo, Marina Konopleva

Blood (2021) 138 (Supplement 1): 3464.

https://doi.org/10.1182/blood-2021-148891

Published: 2021

Journal Articles

Ex Vivo Drug Sensitivity Assay Correlates with Clinical Response and Identifies Panobinostat and Bortezomib As a Potential Novel Drug Combination for Pediatric AML

Debbie C Strachan, Christine Gu, Ryosuke Kita, Michelle A Richardson, Erica K Anderson, Alan K Gonzalez, Noah J Keogh, Hailey H Oviedo, Michelle C Alozie, Raushan Rashid, Maci Terrell, Andrea N Marcogliese, Marianne T Santaguida, Alexandra McLean Stevens

Blood (2021) 138 (Supplement 1): 2361.

https://doi.org/10.1182/blood-2021-145275

Published: 2021

Journal Articles

Characterization Of a Weakly Expressed KIR2DL1 Allele

Hongchuan Li, MD, PhD, Andrew R Huehn, Postbaccalaureate Fellow, Paul W Wright, Research Biologist, Sarah Cooley, MD, Jeffrey S. Miller, MD, Stephen K Anderson, Ph.D.

Blood (2013) 122 (21): 4847.

https://doi.org/10.1182/blood.V122.21.4847.4847

Published: 2013

Journal Articles

Functional NK Cell Repertoires Are Determined By Survival Mechanisms Through IL-2Ra and FasL

Martin Felices, PhD, Todd Lenvik, Dave Ankarlo, Bree Foley, PhD, Julie Curtsinger, PhD, Bruce R Blazar, MD, Stephen K Anderson, Ph.D., Jeffrey S. Miller, MD

Blood (2013) 122 (21): 786.

https://doi.org/10.1182/blood.V122.21.786.786

Published: 2013

Journal Articles

Accelerated progression of chronic lymphocytic leukemia in Eμ-TCL1 mice expressing catalytically inactive RAG1

Vincent K. Nganga, Victoria L. Palmer, Hina Naushad, Michele D. Kassmeier, Dirk K. Anderson, Greg A. Perry, Nathan M. Schabla, Patrick C. Swanson

Blood (2013) 121 (19): 3855–3866.

https://doi.org/10.1182/blood-2012-08-446732

Published: 2013

Includes: Supplemental data

Journal Articles

CD8 T cells express randomly selected KIRs with distinct specificities compared with NK cells

Niklas K. Björkström, Vivien Béziat, Frank Cichocki, Lisa L. Liu, Jeffrey Levine, Stella Larsson, Richard A. Koup, Stephen K. Anderson, Hans-Gustaf Ljunggren, Karl-Johan Malmberg

Blood (2012) 120 (17): 3455–3465.

https://doi.org/10.1182/blood-2012-03-416867

Published: 2012

Includes: Supplemental data

Journal Articles

Mouse Ly49G2 + NK cells dominate early responses during both immune reconstitution and activation independently of MHC

Isabel Barao, Maite Alvarez, Erik Ames, Mark T. Orr, Heather E. Stefanski, Bruce R. Blazar, Lewis L. Lanier, Stephen K. Anderson, Doug Redelman, William J. Murphy

Blood (2011) 117 (26): 7032–7041.

https://doi.org/10.1182/blood-2010-11-316653

Published: 2011

Includes: Supplemental data

Journal Articles

A novel role for IL-22R1 as a driver of inflammation

Ram Savan, Adelle P. McFarland, Della A. Reynolds, Lionel Feigenbaum, Karthika Ramakrishnan, Megan Karwan, Hidekazu Shirota, Dennis M. Klinman, Kieron Dunleavy, Stefania Pittaluga, Stephen K. Anderson, Raymond P. Donnelly, Wyndham H. Wilson, Howard A. Young

Blood (2011) 117 (2): 575–584.

https://doi.org/10.1182/blood-2010-05-285908

Published: 2011

Includes: Supplemental data

Journal Articles

The transcription factor c-Myc enhances KIR gene transcription through direct binding to an upstream distal promoter element

Frank Cichocki, Rebecca J. Hanson, Todd Lenvik, Michelle Pitt, Valarie McCullar, Hongchuan Li, Stephen K. Anderson, Jeffrey S. Miller

Blood (2009) 113 (14): 3245–3253.

https://doi.org/10.1182/blood-2008-07-166389

Published: 2009

Journal Articles

Antisense Transcripts Negatively Regulate Transcription of Multiple Variegated Killer Immunoglobulin-Like Receptor ( KIR ) Genes

Frank Cichocki, Todd Lenvik, Stephen K Anderson, Jeffrey S. Miller, MD

Blood (2008) 112 (11): 105.

https://doi.org/10.1182/blood.V112.11.105.105

Published: 2008

Journal Articles

STAT5A Overexpression Enhances Killer Immunoglobulin Receptor (KIR) Expression in Developing NK Cells and Is Associated with a Loss of Reverse Transcription from the Proximal KIR Promoter.

Frank M. Cichocki, Todd Lenvik, Stephen K. Anderson, PhD, Jeffrey S. Miller, MD

Blood (2007) 110 (11): 798.

https://doi.org/10.1182/blood.V110.11.798.798

Published: 2007

Journal Articles

Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.

Blood (2007) 110 (11): 1170.

https://doi.org/10.1182/blood.V110.11.1170.1170

Published: 2007

Journal Articles

Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.

Blood (2007) 110 (11): 1164.

https://doi.org/10.1182/blood.V110.11.1164.1164

Published: 2007

Journal Articles

Hematologic Profiles in the Phase 3 APEX Trial.

Sagar Lonial, P. Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, H. Goldschmidt, D. Reece, J. San Miguel, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson

Blood (2005) 106 (11): 3474.

https://doi.org/10.1182/blood.V106.11.3474.3474

Published: 2005

Journal Articles

A Multicenter Phase II Trial of Bortezomib in Patients with Previously Untreated Multiple Myeloma: Efficacy with Manageable Toxicity in Patients with Unexpectedly High Rates of Baseline Peripheral Neuropathy.

Blood (2005) 106 (11): 2548.

https://doi.org/10.1182/blood.V106.11.2548.2548

Published: 2005

Journal Articles

A Phase 1 Trial of Lenalidomide (REVLIMID ® ) with Bortezomib (VELCADE ® ) in Relapsed and Refractory Multiple Myeloma.

Blood (2005) 106 (11): 365.

https://doi.org/10.1182/blood.V106.11.365.365

Published: 2005

Journal Articles

Pharmacogenomics (PGx) Research in the APEX Randomized Multicenter International Phase 3 Trial Comparing Bortezomib and High-Dose Dexamethasone (Dex).

G. Mulligan, C. Mitsiades, B. Bryant, F. Zhan, W. Cheng, S. Eschrich, B. Burrington, P. Richardson, W. Trepicchio, J. Shaughnessy, L. Bergsagel, A. Damokosh, A. Boral, D. Esseltine, D. Schenkein, K. Anderson

Blood (2005) 106 (11): 3491.

https://doi.org/10.1182/blood.V106.11.3491.3491

Published: 2005

NARROW

GATA1 and GATA2 Sense/Antisense Transcriptional Switching in Early Hematopoietic Development

In vivo HSC prime editing rescues sickle cell disease in a mouse model

Prediction of Clinical Response to Venetoclax Plus Decitabine in AML Using a 7-Day Ex Vivo Assay

Ex Vivo Drug Sensitivity Assay Correlates with Clinical Response and Identifies Panobinostat and Bortezomib As a Potential Novel Drug Combination for Pediatric AML

Characterization Of a Weakly Expressed KIR2DL1 Allele

Functional NK Cell Repertoires Are Determined By Survival Mechanisms Through IL-2Ra and FasL

Accelerated progression of chronic lymphocytic leukemia in Eμ-TCL1 mice expressing catalytically inactive RAG1

CD8 T cells express randomly selected KIRs with distinct specificities compared with NK cells

Mouse Ly49G2 + NK cells dominate early responses during both immune reconstitution and activation independently of MHC

A novel role for IL-22R1 as a driver of inflammation

The transcription factor c-Myc enhances KIR gene transcription through direct binding to an upstream distal promoter element

Antisense Transcripts Negatively Regulate Transcription of Multiple Variegated Killer Immunoglobulin-Like Receptor ( KIR ) Genes

STAT5A Overexpression Enhances Killer Immunoglobulin Receptor (KIR) Expression in Developing NK Cells and Is Associated with a Loss of Reverse Transcription from the Proximal KIR Promoter.

Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.

Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.

Hematologic Profiles in the Phase 3 APEX Trial.

Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail.

A Multicenter Phase II Trial of Bortezomib in Patients with Previously Untreated Multiple Myeloma: Efficacy with Manageable Toxicity in Patients with Unexpectedly High Rates of Baseline Peripheral Neuropathy.

A Phase 1 Trial of Lenalidomide (REVLIMID ® ) with Bortezomib (VELCADE ® ) in Relapsed and Refractory Multiple Myeloma.

Pharmacogenomics (PGx) Research in the APEX Randomized Multicenter International Phase 3 Trial Comparing Bortezomib and High-Dose Dexamethasone (Dex).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only